<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[QurCan Therapeutics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=52120></link><description><![CDATA[QurCan Therapeutics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 16 Sep 2026 18:21:32 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/09/12_1028147215_20260916160740_3565854286.png]]></url></image><language>ko-KR</language><item><title><![CDATA[큐어캔 테라퓨틱스, 중추 및 말초신경계 질환 핵산 치료제 개발 위해 릴리와 전략적 연구·협력 계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1042755</link><description><![CDATA[토론토, 캐나다--(Business Wire/뉴스와이어)--독자적인 TERP™(표적 공학 반응성 고분자, Target-Engineered Responsive Polymer) 플랫폼을 통해 유전 의약품의 비바이러스성 고분자-지질 나노입자(polymer-lipid nanoparticle, PLNP) 전달 기술을 개척하고 있는 바이오테크 기업 큐어캔 테라퓨틱스(QurCan Therapeutics, 이하 큐어캔)는 중추신경계(CNS) 및 말초신경계(PNS) 질환 치료를 위해 일라이 릴리 앤드 컴퍼니(E...]]></description><pubDate>Wed, 16 Sep 2026 16:35:00 +0900</pubDate></item><item><title><![CDATA[QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1042756</link><description><![CDATA[TORONTO--(Business Wire/Korea Newswire)--QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of di...]]></description><pubDate>Wed, 16 Sep 2026 16:35:00 +0900</pubDate></item></channel></rss>